NCT04820205

Brief Summary

In Korea, oral chloral hydrate is still widely used for pediatric procedural sedation. The primary objective of the study is to evaluate the effect of intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) on the first-attempt success rate of pediatric procedural sedation. The hypothesis of this study is that the intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) will improve the success rate of adequate pediatric procedural sedation (PSSS=1,2,3) within 15 minutes. This is a prospective, parallel-arm, single-blinded, multi-center, randomized controlled trial comparing the effect of intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) with oral chloral hydrate (50mg/kg) in pediatric patients undergoing procedural sedation. Prior to the procedure, each patient will be randomized in the control arm (oral chloral hydrate) or study arm (intranasal dexmedetomidine and ketamine).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
136

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 19, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 29, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

October 29, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2024

Completed
Last Updated

October 9, 2024

Status Verified

October 1, 2024

Enrollment Period

2.4 years

First QC Date

March 19, 2021

Last Update Submit

October 5, 2024

Conditions

Keywords

pediatricprocedural sedationchloral hydrateintranasal dexmedetomidineintranasal ketamine

Outcome Measures

Primary Outcomes (1)

  • Success rate of adequate sedation (PSSS= 1,2,3) within 15 minutes %

    Success rate of adequate sedation (Pediatric Sedation State Scale= 1,2,3) within 15 minutes after sedative administration. %

    During pediatric procedural sedation (up to 1 hour)

Secondary Outcomes (21)

  • Onset time of sedation (PSSS= 0,1,2,3) (min)

    During pediatric procedural sedation (up to 3 hour)

  • Duration of sedation = Recovery time (PSSS= 4,5) (min)

    During pediatric procedural sedation (up to 3 hour)

  • PSSS(Pediatric Sedation State Scale, 0-5)

    During pediatric procedural sedation (up to 3 hour)

  • Heart rate during sedation (/min)

    During pediatric procedural sedation (up to 3 hour)

  • SpO2 during sedation (%)

    During pediatric procedural sedation (up to 3 hour)

  • +16 more secondary outcomes

Study Arms (2)

intranasal dexmedetomdine and kemtaine

EXPERIMENTAL

Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Drug: Intranasal dexmedetomidine and ketamine

oral chloral hydrate

ACTIVE COMPARATOR

Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Drug: Oral chloral hydrate

Interventions

Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

intranasal dexmedetomdine and kemtaine

Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

oral chloral hydrate

Eligibility Criteria

AgeUp to 7 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Pediatric patients who need procedural sedation (Age \< 7 years)
  • ASA (American Society of Anesthesiologists) physical status 1-3

You may not qualify if:

  • ASA (American Society of Anesthesiologists) physical status 4-5
  • History of hypersensitivity to Dexmedetomidine, Ketamine, or Chloral hydrate
  • Recent administration of Alpha 2 adrenergic receptor agonist or antagonist
  • Cannot administrate oral medication (e.g. Swallowing difficulty)
  • Cannot administrate intranasal medication(e.g. Excessive rhinorrhea)
  • Unstable vital signs, Unstable arrhythmia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jin-Tae Kim

Seoul, South Korea

Location

Related Publications (9)

  • Zhang W, Wang Z, Song X, Fan Y, Tian H, Li B. Comparison of rescue techniques for failed chloral hydrate sedation for magnetic resonance imaging scans--additional chloral hydrate vs intranasal dexmedetomidine. Paediatr Anaesth. 2016 Mar;26(3):273-9. doi: 10.1111/pan.12824. Epub 2015 Dec 30.

    PMID: 26714442BACKGROUND
  • Cao Q, Lin Y, Xie Z, Shen W, Chen Y, Gan X, Liu Y. Comparison of sedation by intranasal dexmedetomidine and oral chloral hydrate for pediatric ophthalmic examination. Paediatr Anaesth. 2017 Jun;27(6):629-636. doi: 10.1111/pan.13148. Epub 2017 Apr 17.

    PMID: 28414899BACKGROUND
  • Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15.

    PMID: 24237879BACKGROUND
  • Zanaty OM, El Metainy SA. A comparative evaluation of nebulized dexmedetomidine, nebulized ketamine, and their combination as premedication for outpatient pediatric dental surgery. Anesth Analg. 2015 Jul;121(1):167-171. doi: 10.1213/ANE.0000000000000728.

    PMID: 25822924BACKGROUND
  • Zhang W, Fan Y, Zhao T, Chen J, Zhang G, Song X. Median Effective Dose of Intranasal Dexmedetomidine for Rescue Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging. Anesthesiology. 2016 Dec;125(6):1130-1135. doi: 10.1097/ALN.0000000000001353.

    PMID: 27627818BACKGROUND
  • Jun JH, Kim KN, Kim JY, Song SM. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. Can J Anaesth. 2017 Sep;64(9):947-961. doi: 10.1007/s12630-017-0917-x. Epub 2017 Jun 21.

    PMID: 28639236BACKGROUND
  • Abdel-Ghaffar HS, Kamal SM, El Sherif FA, Mohamed SA. Comparison of nebulised dexmedetomidine, ketamine, or midazolam for premedication in preschool children undergoing bone marrow biopsy. Br J Anaesth. 2018 Aug;121(2):445-452. doi: 10.1016/j.bja.2018.03.039. Epub 2018 Jun 22.

    PMID: 30032884BACKGROUND
  • Poonai N, Canton K, Ali S, Hendrikx S, Shah A, Miller M, Joubert G, Rieder M, Hartling L. Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. PLoS One. 2017 Mar 20;12(3):e0173253. doi: 10.1371/journal.pone.0173253. eCollection 2017.

    PMID: 28319161BACKGROUND
  • Jang YE, Joo EY, Lee JH, Kim EH, Kang P, Park JB, Kim HS, Kim JT. Two-center randomized controlled trial comparing oral chloral hydrate and intranasal combination of dexmedetomidine and ketamine for procedural sedation in children: study protocol. Trials. 2023 Jan 3;24(1):2. doi: 10.1186/s13063-022-07033-x.

MeSH Terms

Interventions

KetamineChloral Hydrate

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsEthylene GlycolsGlycolsAlcohols

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 19, 2021

First Posted

March 29, 2021

Study Start

October 29, 2021

Primary Completion

March 5, 2024

Study Completion

March 5, 2024

Last Updated

October 9, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations